HumateP

Product Specs	Description
Manufacturer Name	CSL Behring
Indications	Hemophilia A – Treatment and prevention of bleeding in adults. Von Willebrand disease (VWD) – in adults and pediatric patients for: (1) Treatment of spontaneous and trauma-induced bleeding episodes, and (2) Prevention of excessive bleeding during and after surgery. This applies to patients with severe VWD as well as patients with mild to moderate VWD where the use of desmospressin is known or suspected to be inadequate. Humate-P is not indicated for the prophylaxis of spontaneous bleeding episodes in VWD.
Contraindications	Anaphylactic or severe systemic reaction to antihemophilic factor or VWF preparations.
Ratio of VWF: RCO to FVIII	2:4:1
Viral Safety Process	Cryoprecipitation, Al(OH)3 adsorption, glycine precipitation, and NaCl precipitation, heat treatment.
Product Half-Life	8.4 to 17.4 hours
Product Recovery Percentage	2.0 IU/dL rise per IU/kg
Manufacturing Methods	Plasma Derived
Storage Requirements/Shelf Life	Stable for 36 months up to the expiration date when stored at temperatures up to 25°C (77°F). Do not freeze. Use within 3 hours of reconstitution.
Nominal Vial Size & Diluent Volume	600 IU/5 mL 1200 IU/10 mL 2400 IU/15 mL

About